Physician profile
Gerald A Colvin
NPI 1417954199
$233,152.67
in general payments reported to CMS, 2019-2025
70 companies · $8,658 in 2025
The $8,658 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $14K · 2021: $27K · 2022: $56K · 2023: $42K · 2024: $44K · 2025: $8,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $30K · Food and Beverage: $8,939 · Honoraria: $1,713 · Education: $1,039 · Travel and Lodging: $96.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,103.25 |
| Consulting Fee | $30,308.50 |
| Food and Beverage | $8,938.62 |
| Honoraria | $1,713.00 |
| Education | $1,039.28 |
| Travel and Lodging | $96.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81,740.03 | 2019-2025 | Opdivo, Eliquis, Camzyos |
| Rigel Pharmaceuticals, INC. | $51,340.75 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $30,588.50 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Adc Therapeutics America, INC. | $16,924.82 | 2021-2025 | |
| Janssen Biotech, INC. | $14,416.91 | 2021-2025 | Imbruvica, Erleada, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $6,455.66 | 2022-2023 | Imbruvica |
| Regeneron Pharmaceuticals, INC. | $5,243.83 | 2023-2024 | Libtayo |
| Celgene Corporation | $4,686.72 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Pharmaceuticals, INC | $3,755.30 | 2021-2024 | Xarelto |
| Kite Pharma, INC. | $3,534.67 | 2020-2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $1,445.13 | 2021-2022 | |
| Sandoz INC. | $1,350.00 | 2025 | |
| Verastem, INC. | $1,320.00 | 2020 | |
| Genentech USA, INC. | $1,250.00 | 2024 | Alecensa, Tecentriq |
| Astellas Pharma US INC | $1,038.80 | 2019-2025 | Padcev, Xtandi, Xospata |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.